Clinical Trial

Human Bioequivalence Study of Amphotericin B Liposome for Injection

Completed
View on ClinicalTrials.gov →
Summary
Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-09; most recent amendment 2026-05-21.
Status change: Recruiting → Completed 2025-11-24
Trial Details
NCT Number NCT06977490
Lead Sponsor Sichuan Huiyu Pharmaceutical Co., Ltd
Collaborators: Changsha King-eagle Med Technology Co., Ltd.
Conditions Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
Enrollment 42 participants
Start Date 2025-05-13
Primary Completion 2025-10-07 (estimated)
Study Completion 2025-10-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-22